Orange Book product · Brand (NDA)
YONSA
ABIRATERONE ACETATE
At a glance
May 22, 2018
Approved
Brand (NDA)
Application
Not listed
TE code
2
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 22, 2018
8 yr 2 mo ago
Today
Patent 9889144 expires
Listed drug product patent expiration.
Mar 17, 2034
in 7 yr 10 mo
Patent 10292990 expires
Listed method-of-use patent (U-2535) expiration.
May 20, 2034
in 8 yr
Pharmaceutical detail
Active ingredient
ABIRATERONE ACETATE
Strength
125MG
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
NDA 210308
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2011ZYTIGABrand (NDA)
NDA 202379 · JANSSEN BIOTECH
- 2023ABIRATERONE ACETATEGeneric (ANDA)
ANDA 215086 · FLORIDA
- 2023ABIRATERONE ACETATEGeneric (ANDA)
ANDA 210726 · TEVA PHARMS USA
- 2022ABIRATERONE ACETATEGeneric (ANDA)
ANDA 212206 · TEVA PHARMS USA
- 2022ABIRATERONE ACETATEGeneric (ANDA)
ANDA 215947 · NOVUGEN
- 2020ABIRATERONE ACETATEGeneric (ANDA)
ANDA 208416 · DR REDDYS
- 2019ABIRATERONE ACETATEGeneric (ANDA)
ANDA 209227 · GLENMARK SPECLT
- 2019ABIRATERONE ACETATEGeneric (ANDA)
ANDA 212462 · QILU
- 2019ABIRATERONE ACETATEGeneric (ANDA)
ANDA 210686 · MSN
- 2019ABIRATERONE ACETATEGeneric (ANDA)
ANDA 208380 · WOCKHARDT BIO AG
- 2019ABIRATERONE ACETATEGeneric (ANDA)
ANDA 208371 · RISING
- 2019ABIRATERONE ACETATEGeneric (ANDA)
ANDA 208327 · AMNEAL PHARMS
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9889144 | Mar 17, 2034 | in 7 yr 10 mo | Product |
| 10292990 | May 20, 2034 | in 8 yr | U-2535 |

